eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2020
vol. 37
 
Share:
Share:
abstract:
Review paper

Resistance of melanoma cells to anticancer treatment: a role of vascular endothelial growth factor

Joanna Bogusławska-Duch
1
,
Magdalena Ducher
1
,
Maciej Małecki
1

  1. Department of Applied Pharmacy, Medical University of Warsaw, Warsaw, Poland
Adv Dermatol Allergol 2020; XXXVII (1): 11-18
Online publish date: 2020/03/09
View full text Get citation
 
Melanoma is one of the most aggressive and resistant to treatment neoplasms. There are still many challenges despite many promising advances in anticancer treatment. Currently, the main problem for all types of treatment is associated with heterogeneity. Due to heterogeneity of cancer cells, “precise” targeting of a medicine against a single phenotype limits the efficacy of treatment and affects resistance to applied therapy. Therefore it is important to understand aetiology and reasons for heterogeneity in order to develop effective and long-lasting treatment. This review summarises roles of vascular endothelial growth factor (VEGF) that may stimulate growth of a melanoma tumour irrespective of its proangiogenic effects, contributing to cancer heterogeneity. VEGF triggers processes associated with extracellular matrix remodelling, cell migration, invasion, angiogenesis, inhibition of immune responses and favours phenotypic plasticity and epithelial-mesenchymal transition. Consequently, it participates in mechanisms of interactions between melanoma cancer cells and microenvironment and it can modify sensitivity to therapeutic factors.
keywords:

cancer, melanoma, vascular endothelial growth factor, resistance to therapy, heterogeneity

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.